Description
Currently in clinical trials for colorectal cancer (CRC), EMD-525797 is being evaluated as a potential treatment option; its efficacy and safety are still under investigation, particularly in patients with refractory or advanced CRC.
Mechanism of Action
EMD-525797 is an investigational drug that targets the Wnt signaling pathway, which plays a critical role in colorectal cancer cell proliferation and survival.
Side Effects
Fatigue; nausea; diarrhea; neutropenia; thrombocytopenia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT01008475
med_phase_prefix1
Archived
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
Belgium, Bulgaria, Cyprus, Czechia, Germany, Greece, Hungary, Israel, Poland, Ru
Quick Info
| Category | Other Medications |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.